Literature DB >> 16096160

ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.

B Lunenfeld1, F Saad, C E Hoesl.   

Abstract

Prescription sales for testosterone products have substantially increased over the last several years reflecting the growing awareness of physicians for the potential benefits of testosterone replacement therapy in men with hypogonadism. Indiscriminate administration of testosterone poses a risk and has to be deprecated. Testosterone supplementation to treat late-onset hypogonadism (LOH), a term for androgen deficiency in elderly men, is still controversially discussed mainly due to a lack of large, controlled clinical trials on efficacy and safety. To provide guidance for physicians primarily dealing with aging men, ISSAM is periodically updating and publishing its recommendations as new data become available [Morales A, Lunenfeld B. International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002;5:74-86 and Morales A, Lunenfeld B. Androgen replacement therapy in aging men with secondary hypogonadism. Draft recommendations for endorsement by ISSAM. Aging Male 2001;4:1]. Following a panel discussion at the 4th ISSAM Congress in Prague in February 2004, the International Society of Andrology (ISA), the International Society for the Study of the Aging Male (ISSAM) and the European Association of Urology (EAU) revised existing recommendations on the definition, diagnosis and management of LOH. The recommendations are based on the currently available scientific data on androgen supplementation therapy and should be regarded as provisional until larger-scale, long-term studies are available. While certainly not intending to be exhaustive, this review will highlight some relevant background information and provide the underlying scientific rationale for the ISA, ISSAM and EAU recommendations on LOH published in this issue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096160     DOI: 10.1080/13685530500163416

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  19 in total

1.  Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial.

Authors:  Seng-Fah Tong; Chirk-Jenn Ng; Boon-Cheok Lee; Verna-K M Lee; Ee-Ming Khoo; Eng-Giap Lee; Hui-Meng Tan
Journal:  Asian J Androl       Date:  2012-05-28       Impact factor: 3.285

Review 2.  Male sexual dysfunction in Asia.

Authors:  Christopher Ck Ho; Praveen Singam; Goh Eng Hong; Zulkifli Md Zainuddin
Journal:  Asian J Androl       Date:  2011-06-06       Impact factor: 3.285

3.  Male Andropause : A Myth or Reality.

Authors:  P R Nandy; D V Singh; P Madhusoodanan; A S Sandhu
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea.

Authors:  Young Hwii Ko; Je Jong Kim
Journal:  Asian J Androl       Date:  2011-05-16       Impact factor: 3.285

5.  Association between body fat distribution and androgen deficiency in middle-aged and elderly men in China.

Authors:  Y Ren; B Wang; X Liu; Z Li; W Yuan; Y Sun; M Miao
Journal:  Int J Impot Res       Date:  2013-12-19       Impact factor: 2.896

Review 6.  Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology.

Authors:  L Antonio; D Vanderschueren; N Narinx; K David; J Walravens; P Vermeersch; F Claessens; T Fiers; B Lapauw
Journal:  Cell Mol Life Sci       Date:  2022-10-07       Impact factor: 9.207

7.  Low serum testosterone increases mortality risk among male dialysis patients.

Authors:  Juan Jesús Carrero; Abdul Rashid Qureshi; Paolo Parini; Stefan Arver; Bengt Lindholm; Peter Bárány; Olof Heimbürger; Peter Stenvinkel
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

8.  Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.

Authors:  Keisuke Okada; Hideaki Miyake; Takaki Ishida; Kenta Sumii; Noritoshi Enatsu; Koji Chiba; Kei Matsushita; Masato Fujisawa
Journal:  Am J Mens Health       Date:  2016-06-02

9.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Male infertility and androgen replacement therapy for subjects with bilateral testicular tumors.

Authors:  Toshiyasu Amano; Tetsuya Imao; Katsuro Takemae
Journal:  Reprod Med Biol       Date:  2013-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.